{"nctId":"NCT04016714","briefTitle":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","startDateStruct":{"date":"2019-08-28","type":"ACTUAL"},"conditions":["Pneumococcal Infections"],"count":1191,"armGroups":[{"label":"V114","type":"EXPERIMENTAL","interventionNames":["Drug: V114","Drug: Vaxelis™","Drug: M-M-R®II","Drug: VARIVAX™"]},{"label":"Prevenar 13™","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prevenar 13™","Drug: Vaxelis™","Drug: M-M-R®II","Drug: VARIVAX™"]}],"interventions":[{"name":"V114","otherNames":["VAXNEUVANCE™","Pneumococcal 15-Valent Conjugate Vaccine"]},{"name":"Prevenar 13™","otherNames":["Prevnar 13™"]},{"name":"Vaxelis™","otherNames":[]},{"name":"M-M-R®II","otherNames":["Measles, Mumps, and Rubella Virus Vaccine Live"]},{"name":"VARIVAX™","otherNames":["Varicella Vaccine Live"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is male or female, approximately 3 months of age, from 70 days to 111 days inclusive, at the time of signing the informed consent.\n* Has a legally acceptable representative who understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent.\n\nExclusion Criteria:\n\n* Was born prior to 37 weeks of gestation.\n* Has a history of invasive pneumococcal disease (IPD) or known history of other culture positive pneumococcal disease.\n* Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine (PCV), any component of the licensed pediatric vaccines to be administered concomitantly in the study, or any diphtheria toxoid containing vaccine.\n* Has any contraindication to the concomitant study vaccines being administered in the study.\n* Has a known or suspected impairment of immunological function.\n* Has a history of congenital or acquired immunodeficiency.\n* Has, or his/her mother has, a documented human immunodeficiency virus (HIV) infection.\n* Has, or his/her mother has, a documented hepatitis B surface antigen - positive test.\n* Has known or history of functional or anatomic asplenia.\n* Has failure to thrive based on the clinical judgement of the investigator.\n* Has a bleeding disorder contraindicating intramuscular vaccination.\n* Has a history of autoimmune disease (including but not limited to systemic lupus erythematosus, antiphospholipid syndrome, Behcet's disease, autoimmune thyroid disease, polymyositis and dermatomyositis, scleroderma, type 1 diabetes mellitus, or other autoimmune disorders).\n* Has a known neurologic or cognitive behavioral disorder, including encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development disorder, and related disorders.\n* Has received a dose of any pneumococcal vaccine prior to study entry.\n* Has received \\>1 dose of monovalent hepatitis B vaccine or hepatitis B-based combination vaccine prior to study entry.\n* Has received a dose of any acellular pertussis- or whole cell pertussis-based combination vaccines, Haemophilus influenza type b conjugate vaccine, poliovirus vaccine, or any other combination thereof, prior to study entry.\n* Has received a blood transfusion or blood products, including immunoglobulins.\n* Has participated in another clinical study of an investigational product before the beginning or anytime during the duration of the current clinical study. Participants enrolled in observational studies may be included; these will be reviewed on a case by-case basis for approval by the Sponsor.\n* Has any other reason that, in the opinion of the investigator, may interfere with the evaluation required by the study. Reasons may include, but are not limited to, being unable to keep appointments or planning to relocate during the study.\n* Is or has an immediate family member (e.g., parent/legal guardian or sibling) who is investigational site or Sponsor staff directly involved with this study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"70 Days","maximumAge":"111 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Solicited Injection-site Adverse Event","description":"An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs included injection-site erythema (redness), injection-site induration (hard lump), injection-site pain (tenderness), and injection-site swelling.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":null},{"groupId":"OG001","value":"59.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":null},{"groupId":"OG001","value":"59.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":null},{"groupId":"OG001","value":"44.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Solicited Systemic Adverse Event","description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs included decreased appetite, irritability, somnolence (drowsiness), and urticaria (hives or welts).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null},{"groupId":"OG001","value":"58.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null},{"groupId":"OG001","value":"94.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null},{"groupId":"OG001","value":"77.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null},{"groupId":"OG001","value":"21.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Vaccine-related Serious Adverse Event","description":"A serious adverse event (SAE) is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs that were reported by the investigator to be at least possibly related to the study vaccination were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Meeting Serotype-specific Immunoglobulin G (IgG) Threshold Value of ≥0.35 μg/mL 30 Days After Dose 3","description":"The geometric mean concentration (GMC) of IgG serotype-specific antibodies to the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevenar 13™ and 2 serotypes (22F and 33F) unique to V114 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay. Immunoglobulin G for the 15 serotypes contained in V114 vaccine was determined using a pneumococcal electrochemiluminescence (PnECL) assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null},{"groupId":"OG001","value":"82.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"98.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"96.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) 30 Days After Dose 3","description":"The GMC of IgG serotype-specific antibodies to the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevenar 13™ and 2 serotypes (22F and 33F) unique to V114 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":null},{"groupId":"OG001","value":"2.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null},{"groupId":"OG001","value":"0.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":null},{"groupId":"OG001","value":"2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.08","spread":null},{"groupId":"OG001","value":"3.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.21","spread":null},{"groupId":"OG001","value":"5.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.56","spread":null},{"groupId":"OG001","value":"5.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null},{"groupId":"OG001","value":"3.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":null},{"groupId":"OG001","value":"3.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.35","spread":null},{"groupId":"OG001","value":"6.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.10","spread":null},{"groupId":"OG001","value":"2.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.74","spread":null},{"groupId":"OG001","value":"6.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.08","spread":null},{"groupId":"OG001","value":"5.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":null},{"groupId":"OG001","value":"1.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.06","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.28","spread":null},{"groupId":"OG001","value":"0.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Meeting Specified Vaxelis™ Antigen Reponses 30 Days After Dose 3","description":"Antigen-specific response rates in participants administered V114 concomitantly with Vaxelis™ were compared with response rates in participants administered Prevenar 13™ concomitantly with Vaxelis™, and the percentages of participants meeting specified Vaxelis™ antigen responses recorded. Antigens in Vaxelis™ include: diphtheria toxoid, tetanus toxoid, pertussis toxin (PT), pertussis filamentous hemagglutinin (FHA), pertussis fimbriae 2/3 (FIM 2/3), pertussis pertactin (PRN), Haemophilus influenzae type b polyribosylribitol phosphate (Hib-PRP), hepatitis B surface antigen (HBsAg), and poliovirus serotypes 1, 2, and 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Meeting Serotype-specific IgG Threshold Value of ≥0.35 μg/mL 30 Days After Dose 2","description":"The GMC of IgG serotype-specific antibodies to the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevenar 13™ and 2 serotypes (22F and 33F) unique to V114 were quantitated from participants' sera by a multiplex ECL assay. Immunoglobulin G for the 15 serotypes contained in V114 vaccine was determined using a PnECL assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"78.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"91.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":null},{"groupId":"OG001","value":"91.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.0","spread":null},{"groupId":"OG001","value":"40.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null},{"groupId":"OG001","value":"94.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"94.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]}]},{"type":"SECONDARY","title":"GMC of Serotype-specific IgG 30 Days After Dose 2","description":"The GMC of IgG serotype-specific antibodies to the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevenar 13™ and 2 serotypes (22F and 33F) unique to V114 were quantitated from participants' sera by a multiplex ECL assay. Immunoglobulin G for the 15 serotypes contained in V114 vaccine was determined using a PnECL assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":null},{"groupId":"OG001","value":"1.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":null},{"groupId":"OG001","value":"0.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.74","spread":null},{"groupId":"OG001","value":"1.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":null},{"groupId":"OG001","value":"1.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":null},{"groupId":"OG001","value":"1.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":null},{"groupId":"OG001","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.69","spread":null},{"groupId":"OG001","value":"2.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":null},{"groupId":"OG001","value":"1.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.59","spread":null},{"groupId":"OG001","value":"5.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":null},{"groupId":"OG001","value":"1.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.70","spread":null},{"groupId":"OG001","value":"2.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.79","spread":null},{"groupId":"OG001","value":"4.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":null},{"groupId":"OG001","value":"0.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.16","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Meeting Specified Opsonophagocytic Activity (OPA) Responses 30 Days After Dose 3","description":"OPA for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevenar 13™ and 2 serotypes unique to V114 (22F and 33F) was measured using a multiplex opsonophagocytic assay (MOPA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"26.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of Serotype-specific OPA 30 Days After Dose 3","description":"Sera from participants was used to measure GMT of the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevenar 13™ and 2 serotypes unique to V114 (22F and 33F) was determined using a MOPA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152.2","spread":null},{"groupId":"OG001","value":"184.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"320.4","spread":null},{"groupId":"OG001","value":"296.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2290.8","spread":null},{"groupId":"OG001","value":"2842.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"855.5","spread":null},{"groupId":"OG001","value":"1024.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3316.8","spread":null},{"groupId":"OG001","value":"4649.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2691.6","spread":null},{"groupId":"OG001","value":"2658.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5819.2","spread":null},{"groupId":"OG001","value":"7839.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2192.1","spread":null},{"groupId":"OG001","value":"2745.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3449.4","spread":null},{"groupId":"OG001","value":"2360.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2203.1","spread":null},{"groupId":"OG001","value":"2003.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2839.1","spread":null},{"groupId":"OG001","value":"3843.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1748.4","spread":null},{"groupId":"OG001","value":"2067.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3650.2","spread":null},{"groupId":"OG001","value":"6776.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2927.9","spread":null},{"groupId":"OG001","value":"29.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13334.7","spread":null},{"groupId":"OG001","value":"1557.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":30,"n":595},"commonTop":["Irritability","Somnolence","Injection site erythema","Injection site pain","Injection site induration"]}}}